Drug Profile

Research programme: Antibody drug conjugate therapeutics - LigaChem Biosciences/Trican Biotechnology

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LigaChem Biosciences; Trican Biotechnology
Class Antibodies; Antifibrotics; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Sep 2025 LigaChem Biosciences and Trican Biotechnology enetered into a research collaboration and exclusive option and license agreement to develop and commercialize a novel ADC therapeutic
10 Sep 2025 Early research in Cancer in South Korea, Taiwan (Parenteral), prior to September 2025
10 Sep 2025 Early research in Fibrosis in Taiwan, South Korea (Parenteral), prior to September 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com